Floatz logo

Lorcaserin

Nicotine Dependence

Mayo ClinicSmall moleculePhase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Nicotine Dependence cohort.

Asset / SponsorPhaseRating
Nicotine
Brown University
Phase 4A
Varenicline
University of California, San Diego
Phase 4A
Naltrexone
Yale University
Phase 4BBB
Semaglutide
University of Oklahoma
Phase 4BBB
Minocycline
University of Maryland, Baltimore
Phase 4BB

View all 26 →

Same molecule, other indications

Lorcaserin is also rated in:

obesity disorderActive
BB
Indicative · Phase 4
66 / 100
View asset →
cardiovascular disorderDormant
B
Indicative · Phase 4
63 / 100
View asset →
schizoaffective disorderDormant
B
Indicative · Phase 4
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →